How Technology Is Transforming Clinical Endpoint Adjudication

When clinical endpoints are subjective, image-based or complex to assess, or the study is geographically broad, researchers of new drugs and devices may find it difficult to demonstrate acceptable safety results to regulatory authorities.

To meet this requirement, trial sponsors and contract research organizations (CROs) are turning to clinical endpoint committees (CEC) for independent event adjudication as the most efficient process to help reduce costs, increase quality, and eliminate clinical bias. CECs reduce variability in adjudicated outcomes since the physicians selected to perform these assessments are often experts in the event type and apply a consistent, standardized approach to the assessment.

There are several ways to implement and manage a CEC. However, traditional manual, paper-based approaches to CEC management place significant time, cost, and resource burdens on organizations—and are prone to errors, bias, and regulatory issues. Read how the right technology gives you control over your timelines and allows you to configure your own trials and can standardize what data is collected and organized.